225 related articles for article (PubMed ID: 23507282)
1. Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia.
Oldach D; Clark K; Schranz J; Das A; Craft JC; Scott D; Jamieson BD; Fernandes P
Antimicrob Agents Chemother; 2013 Jun; 57(6):2526-34. PubMed ID: 23507282
[TBL] [Abstract][Full Text] [Related]
2. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
File TM; Rewerska B; Vucinic-Mihailovic V; Gonong JRV; Das AF; Keedy K; Taylor D; Sheets A; Fernandes P; Oldach D; Jamieson BD
Clin Infect Dis; 2016 Oct; 63(8):1007-1016. PubMed ID: 27448679
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).
Barrera CM; Mykietiuk A; Metev H; Nitu MF; Karimjee N; Doreski PA; Mitha I; Tanaseanu CM; Molina JM; Antonovsky Y; Van Rensburg DJ; Rowe BH; Flores-Figueroa J; Rewerska B; Clark K; Keedy K; Sheets A; Scott D; Horwith G; Das AF; Jamieson B; Fernandes P; Oldach D;
Lancet Infect Dis; 2016 Apr; 16(4):421-30. PubMed ID: 26852726
[TBL] [Abstract][Full Text] [Related]
4. Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.
Zhanel GG; Hartel E; Adam H; Zelenitsky S; Zhanel MA; Golden A; Schweizer F; Gorityala B; Lagacé-Wiens PR; Walkty AJ; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2016 Dec; 76(18):1737-1757. PubMed ID: 27909995
[TBL] [Abstract][Full Text] [Related]
5. Solithromycin monotherapy for treatment of community-acquired bacterial pneumonia: A meta-analysis of randomised controlled trials.
Wen J; Chen F; Zhao M; Wang X
Int J Clin Pract; 2019 May; 73(5):e13333. PubMed ID: 30810253
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia.
Tanaseanu C; Milutinovic S; Calistru PI; Strausz J; Zolubas M; Chernyak V; Dartois N; Castaing N; Gandjini H; Cooper CA;
BMC Pulm Med; 2009 Sep; 9():44. PubMed ID: 19740418
[TBL] [Abstract][Full Text] [Related]
7. Solithromycin for the treatment of community-acquired bacterial pneumonia.
Viasus D; Ramos O; Ramos L; Simonetti AF; Carratalà J
Expert Rev Respir Med; 2017 Jan; 11(1):5-12. PubMed ID: 27753516
[TBL] [Abstract][Full Text] [Related]
8. Solithromycin: A novel ketolide antibiotic.
Buege MJ; Brown JE; Aitken SL
Am J Health Syst Pharm; 2017 Jun; 74(12):875-887. PubMed ID: 28432048
[TBL] [Abstract][Full Text] [Related]
9. Solithromycin in Children and Adolescents With Community-acquired Bacterial Pneumonia.
Lang JE; Hornik CP; Elliott C; Silverstein A; Hornik C; Al-Uzri A; Bosheva M; Bradley JS; Borja-Tabora CFC; Di John D; Mendez Echevarria A; Ericson JE; Friedel D; Gonczi F; Isidro MGD; James LP; Kalocsai K; Koutroulis I; Laki I; Ong-Lim ALT; Nad M; Simon G; Syed S; Szabo E; Benjamin DK; Cohen-Wolkowiez M;
Pediatr Infect Dis J; 2022 Jul; 41(7):556-562. PubMed ID: 35675525
[TBL] [Abstract][Full Text] [Related]
10. The role of solithromycin in the management of bacterial community-acquired pneumonia.
Van Bambeke F; Tulkens PM
Expert Rev Anti Infect Ther; 2016; 14(3):311-24. PubMed ID: 26848612
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
File TM; Segreti J; Dunbar L; Player R; Kohler R; Williams RR; Kojak C; Rubin A
Antimicrob Agents Chemother; 1997 Sep; 41(9):1965-72. PubMed ID: 9303395
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumonia.
Liu Y; Zhang Y; Wu J; Zhu D; Sun S; Zhao L; Wang X; Liu H; Ren Z; Wang C; Xiu Q; Xiao Z; Cao Z; Cui S; Yang H; Liang Y; Chen P; Lv Y; Hu C; Lv X; Liu S; Kuang J; Li J; Wang D; Chang L
J Microbiol Immunol Infect; 2017 Dec; 50(6):811-820. PubMed ID: 26748734
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics and Safety of Solithromycin following Intravenous and Oral Administration in Infants, Children, and Adolescents.
Gonzalez D; James LP; Al-Uzri A; Bosheva M; Adler-Shohet FC; Mendley SR; Bradley JS; Espinosa C; Tsonkova E; Moffett K; Marquez L; Simonsen KA; Stoilov S; Boakye-Agyeman F; Jasion T; Hornik CP; Hernandez R; Benjamin DK; Cohen-Wolkowiez M
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891609
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial.
Yuan J; Mo B; Ma Z; Lv Y; Cheng SL; Yang Y; Tong Z; Wu R; Sun S; Cao Z; Wu J; Zhu D; Chang L; Zhang Y;
J Microbiol Immunol Infect; 2019 Feb; 52(1):35-44. PubMed ID: 30181096
[TBL] [Abstract][Full Text] [Related]
16. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients.
Shorr AF; Khashab MM; Xiang JX; Tennenberg AM; Kahn JB
Respir Med; 2006 Dec; 100(12):2129-36. PubMed ID: 16730170
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of solithromycin and levofloxacin against a murine pneumonia mixed-infection model caused by Streptococcus pneumoniae and anaerobic bacteria.
Kato H; Yamagishi Y; Hagihara M; Yokoyama Y; Suematsu H; Asai N; Koizumi Y; Mikamo H
J Infect Chemother; 2019 Apr; 25(4):311-313. PubMed ID: 30287186
[TBL] [Abstract][Full Text] [Related]
18. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
[TBL] [Abstract][Full Text] [Related]
19. High-dose levofloxacin in community-acquired pneumonia: a randomized, open-label study.
Lee JH; Kim SW; Kim JH; Ryu YJ; Chang JH
Clin Drug Investig; 2012 Sep; 32(9):569-76. PubMed ID: 22765645
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia.
Frank E; Liu J; Kinasewitz G; Moran GJ; Oross MP; Olson WH; Reichl V; Freitag S; Bahal N; Wiesinger BA; Tennenberg A; Kahn JB
Clin Ther; 2002 Aug; 24(8):1292-308. PubMed ID: 12240780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
